Bausch & Lomb to Market Generic Alphagan Eye Drop

The product is designed for people with open-angle glaucoma or ocular hypertension.
By TSC Staff ,

The Food and Drug Administration approved

Bausch & Lomb's

(BOL)

abbreviated new drug application for a generic form of Alphagan, an eye drop designed to lower intraocular pressure in people with open-angle glaucoma or ocular hypertension.

The company said the FDA granted marketing exclusivity for the generic medication until Sept. 20.

Brimonidine tartrate ophthalmic solution, 0.2%, is sold under the brand name Alphagan and is manufactured by

Allergan

(AGN) - Get Report

, which had tried to block the generic formulation by filing two patent-infringement lawsuits.

Bausch & Lomb's generic version of the prescription eye drop is available immediately. The company makes the product at its pharmaceuticals facility in Tampa.

Shares of Bausch & Lomb closed

New York Stock Exchange

trading Wednesday at $37.20. Allergan ended at $73.12.

Loading ...